Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?
- Registration Number
- NCT00405431
- Lead Sponsor
- Wills Eye
- Brief Summary
The purpose of this study is to determine whether reducing inflammation of the surface of the eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase patient comfort.
- Detailed Description
Continued use of glaucoma drops can alter the outer surface of the eye and result in swelling and irritation, changing the structure of the eye. This structural change has been found to be a significant risk factor for the failure of glaucoma surgery. A comparison of how well patients do after glaucoma surgery depending on whether they use Restasis (the only prescription medication approved by the FDA for treating dry eye) or artificial tears (which can be purchased without a prescription) for 6 months following their surgery.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
- Patients with uncontrolled glaucoma scheduled for filtering surgery
- Under 18 years of age
- Unable to understand informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Endura (artificial tears) Patients receive artificial tears (Endura) during 6 month post-operative period 1 Restasis Patients received restasis eyedrops during 6 month post-operative period
- Primary Outcome Measures
Name Time Method intraocular pressure 6 months
- Secondary Outcome Measures
Name Time Method ocular inflammation 6 months
Trial Locations
- Locations (1)
Wills Eye Glaucoma Service
🇺🇸Philadelphia, Pennsylvania, United States